Literature DB >> 10086830

Comparative safety evaluation of non-narcotic analgesics.

S E Andrade1, C Martinez, A M Walker.   

Abstract

Both spontaneous reports and single outcome studies may distort the overall safety evaluation of drugs. We identified epidemiologic studies, published from January 1970 to December 1995, that investigated the association of serious adverse effects with aspirin, diclofenac, acetaminophen, and dipyrone to determine and compare the excess mortality associated with short-term drug use. The estimated excess mortality due to community-acquired agranulocytosis, aplastic anemia, anaphylaxis, and serious upper gastrointestinal complications was 185 per 100 million for aspirin, 592 per 100 million for diclofenac, 20 per 100 million for acetaminophen, and 25 per 100 million for dipyrone. The estimates were largely influenced by the excess mortality associated with upper gastrointestinal complications. A relative risk estimate of 300 or more for the association of dipyrone with agranulocytosis would have been necessary for the excess mortality of dipyrone to be comparable to that of aspirin or diclofenac. Based on published epidemiologic evidence used to determine the excess mortality associated with short-term use of these four non-narcotic analgesics, the current regulatory ranking of the drugs appears inappropriate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10086830     DOI: 10.1016/s0895-4356(98)00076-6

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  30 in total

1.  Modifications of clonidine binding to rabbit liver protein under the influence of non-steroid-anti-inflammatory drugs in vitro.

Authors:  C Tesserommatis; T Saranteas; E Chatzijanni; S Anagnostopoulou; A Cotsiou; C Chatzi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jul-Sep       Impact factor: 2.441

2.  Assessment of a new instrument for detecting preventable adverse drug reactions.

Authors:  Raja Benkirane; Rachida Soulaymani-Bencheikh; Asmae Khattabi; Ghita Benabdallah; Loubna Alj; Houda Sefiani; Khedidja Hedna; Lahcen Ouammi; Sten Olsson; Shanti N Pal
Journal:  Drug Saf       Date:  2015-04       Impact factor: 5.606

Review 3.  Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury: systematic review and meta-analysis.

Authors:  Peter Jones; Rain Lamdin
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports.

Authors:  Lea S Blaser; Alexandra Tramonti; Pascal Egger; Manuel Haschke; Stephan Krähenbühl; Alexandra E Rätz Bravo
Journal:  Eur J Clin Pharmacol       Date:  2014-11-18       Impact factor: 2.953

5.  Use of Neo-melubrina, a banned antipyretic drug, in San Diego, California: a survey of patients and providers.

Authors:  L Taylor; S Abarca; B Henry; L Friedman
Journal:  West J Med       Date:  2001-09

Review 6.  [Paracetamol. Efficacious and safe for all ages].

Authors:  M Wehling
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

Review 7.  [Pain assessment and pain treatment in the geriatric patient. Part II: pain treatment].

Authors:  H D Basler; N Griessinger; U Hankemeier; D Märkert; Th Nikolaus; W Sohn
Journal:  Schmerz       Date:  2005-02       Impact factor: 1.107

Review 8.  [Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?]

Authors:  P Bahrmann; M Christ
Journal:  Herz       Date:  2018-05       Impact factor: 1.443

Review 9.  Single dose dipyrone (metamizole) for acute postoperative pain in adults.

Authors:  Leslie Hearn; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-04-20

10.  Gastrointestinal tolerability of metamizol, acetaminophen, and diclofenac in subchronic treatment in rats.

Authors:  Susana Sánchez; Catalina Alarcón de la Lastra; Pablo Ortiz; Virginia Motilva; M José Martín
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.